Cargando…

Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

BACKGROUND: To assess the oncologic outcomes of radiation therapy (RT) combined with maximal androgen blockade (MAB) and prostate-specific antigen (PSA) kinetics in patients with localized, high-risk prostate carcinoma (PCa). METHODS: Three-hundred twenty individuals with localized PCa who underwent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yong, Li, Mingchuan, Qi, Hengzhi, Zhao, Jiahui, Han, Yili, Lin, Yunhua, Hou, Zhu, Jiang, Yongguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996541/ https://www.ncbi.nlm.nih.gov/pubmed/29890979 http://dx.doi.org/10.1186/s12957-018-1395-5

Ejemplares similares

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo
por: HAN, YILI, et al.
Publicado: (2014)

Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity
por: Luo, Yong, et al.
Publicado: (2020)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients
por: Luo, Yong, et al.
Publicado: (2021)

β-catenin nuclear translocation induced by HIF-1α overexpression leads to the radioresistance of prostate cancer
por: Luo, Yong, et al.
Publicado: (2018)

Oncological Outcomes of Patients With Different Pathological Features of pT3a Renal Tumor: A Systematic Review and Quantitative Synthesis
por: Guo, Pengju, et al.
Publicado: (2021)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade
por: Wang, Ning, et al.
Publicado: (2019)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Role of maximum androgen blockade in advanced prostate cancer
por: Ayyathurai, Rajinikanth, et al.
Publicado: (2009)

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
por: Sartor, Oliver, et al.
Publicado: (2023)

MicroRNA-149 inhibits cancer cell malignant phenotype by regulating Akt1 in C4-2 CRPC cell line
por: Zhao, Jiahui, et al.
Publicado: (2021)

Establishment and validation of a nomogram for predicting the surgical difficulty of lateral retroperitoneal laparoscopic adrenalectomy
por: Zhao, Jiahui, et al.
Publicado: (2022)

Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer
por: Kang, Yu Jin, et al.
Publicado: (2014)

Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
por: Fujimura, Tetsuya, et al.
Publicado: (2018)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
por: Thalgott, Mark, et al.
Publicado: (2014)

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
por: Mellado, B, et al.
Publicado: (2009)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

Pure retroperitoneal natural orifice translumenal endoscopic surgery (NOTES) transvaginal nephrectomy using standard laparoscopic instruments: a safety and feasibility study in a porcine model
por: Wei, Dechao, et al.
Publicado: (2016)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

Identification of a pyroptosis related gene signature for predicting prognosis and estimating tumor immune microenvironment in bladder cancer
por: Zhao, Jiahui, et al.
Publicado: (2022)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway
por: Luo, Yong, et al.
Publicado: (2021)

The abscopal effect of local radiotherapy is induced by TGFβ blockade
por: Diamond, Julie, et al.
Publicado: (2013)

Establishment and validation of a nomogram for predicting perioperative complications of retroperitoneal laparoscopic adrenalectomy
por: He, Jing, et al.
Publicado: (2023)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Comparison of Oncological Outcomes Between Radical Prostatectomy and Radiotherapy by Type of Radiotherapy in Elderly Prostate Cancer Patients
por: Guo, Xiao-Xiao, et al.
Publicado: (2021)

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011)

Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer
por: Kondo, Takeshi, et al.
Publicado: (2016)

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
por: Payne, H, et al.
Publicado: (2011)

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
por: Lu, Yu-Cheng, et al.
Publicado: (2022)

Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature
por: Cartes, Rodrigo, et al.
Publicado: (2023)

Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma
por: McVorran, Shauna, et al.
Publicado: (2022)

Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group
por: Scher, Nathaniel, et al.
Publicado: (2019)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

Novel case of androgen receptor‐positive cancer of unknown primary without serum prostate‐specific antigen elevation that became progression free in the long term after primary combined androgen blockade
por: Matsuyama, Nayuka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hd2ebivfbm3qt56p9kupc6rcem